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Abstract
Background: Congenital Cytomegalovirus (CMV) infection is an important medical problem that has yet no current
solution. A clinical trial of CMV glycoprotein B (gB) vaccine in young women showed promising efficacy. Improved
understanding of the basis for prevention of CMV infection is essential for developing improved vaccines.
Results: We genotyped 142 women previously vaccinated with three doses of CMV gB for single nucleotide
polymorphisms (SNPs) in TLR 1-4, 6, 7, 9, and 10, and their associated intracellular signaling genes. SNPs in the
platelet-derived growth factor receptor (PDGFRA) and integrins were also selected based on their role in binding
gB. Specific SNPs in TLR7 and IKBKE (inhibitor of nuclear factor kappa-B kinase subunit epsilon) were associated
with antibody responses to gB vaccine. Homozygous carriers of the minor allele at four SNPs in TLR7 showed
higher vaccination-induced antibody responses to gB compared to heterozygotes or homozygotes for the
common allele. SNP rs1953090 in IKBKE was associated with changes in antibody level from second to third dose
of vaccine; homozygotes for the minor allele exhibited lower antibody responses while homozygotes for the major
allele showed increased responses over time.
Conclusions: These data contribute to our understanding of the immunogenetic mechanisms underlying
variations in the immune response to CMV vaccine.
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Background
Infection with CMV is common in humans, causing
severe morbidity and mortality in congenitally-infected
newborns and in immunocompromised patients [1-3].
The importance of CMV as the leading infectious cause
of mental retardation and deafness in children has been
emphasized by its categorization by the Institute of Medi-
cine as a level I vaccine candidate [4]. The rationale for
developing a CMV vaccine is based on clinical and ani-
mal studies showing that immunity to CMV reduces the
frequency and severity of disease [5,6]. In addition, ani-
mal studies demonstrated that immunization with subu-
nit vaccines prevented disease and transplacental
transmission of CMV [5-7]. Two recent phase II clinical
trials with glycoprotein B (gB)-MF59 led to major enthu-
siasm and hope for the future success of CMV vaccine.
The first was performed in young women recruited on
postpartum wards [4], and showed 50% efficacy in pre-
venting maternal CMV infection. Analysis of antibody
levels to gB among vaccine recipients revealed that all
women developed antibodies to gB although the levels
and kinetics of antibody responses varied. The second
study recruited patients from the kidney/liver transplant
waiting list, and showed that antibody titers against gB
were significantly increased one month after the second
injection in patients given the vaccine compared with
those given placebo, and that antibody titers to gB pre-
transplant correlated inversely with the duration of vire-
mia, and the need for therapy with ganciclovir after
transplant [8].
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Data from human studies suggest that single nucleotide
polymorphisms (SNPs) in immune response genes may
influence severity of infections and response to vaccina-
tions such as rubella, measles and hepatitis B [9-16]. Toll-
like receptors (TLR) play a key role in the innate immune
system and have been implicated in infectious and autoim-
mune processes [17]. CMV gB and glycoprotein gH (gH)
associate with and activate TLR2/1, mediating an initial
signal transduction pathway leading to upregulation of
NF-kB and SP-1 [18,19]. In liver transplant recipients
TLR2 R753Q SNP was associated with CMV replication
and disease [20]. The successful gB vaccine trial in young
women provided us with a unique opportunity to deter-
mine whether antibody responses to gB vaccine were
influenced by SNPs in TLR genes.
Methods
Study population
The study cohort included healthy women who were
enrolled in the CMV vaccine after obtaining written
informed consent [4]. Women were screened on the
postpartum wards, and those who were negative for anti-
body to CMV were invited to participate in the clinical
trial. Study participants received a fixed dose of vaccine
consisting of recombinant CMV envelope glycoprotein B
(0.02 mg) with MF59 adjuvant (13.25 mg). The Johns
Hopkins University School of Medicine and University of
Alabama Institutional Review Boards granted approval
for this study.
Antibody assays
Antibody to CMV gB was measured using an Enzyme-
linked immunoabsorbent assay (ELISA) [21]. The vaccine
antigen, a recombinant gB molecule from Towne CMV
(provided by Sanofi Pasteur, Marcy L’Etoile, France) was
used.
SNP selection
Using a candidate gene approach the following genes were
selected: TLRs and associated intracellular signaling mole-
cules: TLR1-4, TLR6, TLR7, TLR9, TLR10, JUN, MYD88,
IKBKE, CHUK (IKKa), NF-KB1, CD14, MXD3 (MAD3),
MAPK8 (JNK1), MAPK14, MAP3K7 (TAK1), LY96
(MD2), TRAF6, IRAK1, IRAK4, TBK1, TICAM1 (TRIF)
and IRF3. In addition, PDGFRA, PDGFRB and integrin
alpha V and integrin B1 were selected based on data show-
ing their role in binding gB [22,23].
We identified tagging SNPs within the genes and in the
10 kb flanking each side of the genes, using the LDselect
algorithm in individuals from the publicly available Hap-
Map Yoruba, Nigeria population (YRI) [24]. For tagging
SNPs we used an r2 > 0.8. SNPs with a high r2 are corre-
lated and can give information about each other, so they
are grouped together and one SNP is selected to represent
them all. This is known as a “tagging” SNP. Selection was
restricted to those SNPs with a minor allele frequency
(MAF) > 1% in the African population. Additionally, all
SNPs were evaluated using a proprietary algorithm from
Illumina, Inc. (San Diego, CA) which assesses the likeli-
hood that an assay will succeed on the Illumina genotyp-
ing platform. Only those with a design score > 0.8 were
selected for use. For non-synonymous SNPs we used a
more liberal cut off score > 0.4 to ensure inclusion of
functional variants. Forty-one additional SNPs with pre-
viously reported associations in a variety of human dis-
eases, 157 non-synoymous SNPs, and 28 ancestry
informative markers (AIMs) were also typed for a total of
702 SNPs. African Americans are typically individuals with
a mixed ethnic background. Allele frequencies of SNPs
can vary by race and ethnicity. Therefore, it is important
to assess the degree of mixture in an admixed individual
when analyzing SNP data. If the cases and controls have
differing amounts of admixture, variation in allele fre-
quency by race can cause the appearance of an association
with the phenotype of interest, when in reality the associa-
tion is with race. Including AIMs in the SNP panel allows
an assessment of admixture and means that differing
amounts of admixture can be controlled for in the data
analysis.
Genotyping methods
Genomic DNA (samples, 75-150 ng/μl each) and 200-
400 ng/μl (whole genome amplified DNA each) were
obtained from frozen EDTA-blood samples using Gen-
tra Puregene extraction (Qiagen). The study samples
and duplicates were plated and genotyped together with
33 HapMap controls (21 CEU; 12 YRI). Genotyping was
performed using the Illumina GoldenGate chemistry.
Allele cluster definitions for each SNP were initially
determined by Illumina’s BeadStudio Genotyping Mod-
ule (version 3.3.7) clustering algorithm using all samples
in the project, applying a quality threshold (Gencall
score) of 0.25. This was followed by manual review of
the cluster definition for each SNP and adjustment of
cluster boundaries to drop questionable genotype calls.
Statistical analysis
28 ancestry informative markers were genotyped for
evaluation of population stratification using principal
components (PCA) in the statistical program Eigenstrat
[25]. Six HapMap populations from Phase III (CEU,
ASW, TSI, YRI, MKK and LWK) were also included.
PCA was performed using the 28 AIMs and an addi-
tional 55 SNPs from the candidate genes without any
linkage disequilibrium (LD). This second analysis did
not increase the ability to discriminate between different
ethnic groups, so only the results from the first analysis
were incorporated into the regression as covariates,
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using the ten first principal components. Association
analyses were done in PLINK, version 1.062. A principal
component analysis (PCA) was applied to correct for
potential confounding due to ancestry. A similar distri-
bution of antibody levels was found among those of
European and African ancestry (Additional file 1: Figure
S1). In addition, quantile- quantile plots (QQ plots)
including lambda values indicated that there was no
increased stratification in our study population (Addi-
tional file 2: Figure S2). http://pngu.mgh.harvard.edu.
ezproxy.welch.jhmi.edu/~purcell/plink/gplink.shtml
using linear regression and an additive model. A Hardy-
Weinberg p-value threshold of 10-3 and a minor allele
frequency (MAF) greater than 0.01 were used. A cut off
at p value ≤ 0.03 was selected.
Results
The study cohort was primarily African American (75%)
with a median age of 19.6 years (range 14-40 years).
SNP data were available from 152 women who received
gB vaccine (99% of attempted samples). Of 152 vaccine
recipients, 142 received 3 doses of vaccine and had data
available on both genotypes and ELISA titers. The titer of
gB antibodies six month after administration of 3rd vaccine
ranged from 370-86,732 (median- 9847.7).
The first goal was to determine whether genetic varia-
tion within TLR genes contributed to the observed anti-
body responses to CMV gB vaccine. Linear regression was
performed of individuals’ log transformed ELISA levels
measured 6 months after the third dose of vaccine. SNPs
yielding p-value < 0.03 are summarized in Table 1. Four
SNPs in TLR7 (rs179008, rs179009, rs179013 and
rs179018) appeared to influence the level of antibodies to
gB (Table 1). The linear regression model included poten-
tial confounding effects of age, race, educational level, and
number of children. Results were similar without adjusting
for these covariates (data not shown).
Homozygous carriers of the minor allele at four SNPs
in the TLR7 gene showed higher vaccination-induced
antibody responses to gB compared to heterozygotes or
homozygotes for the common TLR7 allele (Table 1).
Three of these four SNPs (rs179009, rs179013, and
rs179018) are located in the intronic regions. Rs179008
and rs1790099 are in strong linkage disequilibrium
(Figure 1).
Next, a possible association of SNPs in TLRs with
changes in antibody responses from one month after the
second dose of vaccine to six months following the third
(and last) dose was investigated. For this analysis, we used
data from 69 women who initially were at the top 50% of
responses (a cut off of 9,506.5 ELISA units was used), and
then the change in antibody levels following the last dose
of vaccine. Data were compared between women who had
no change or an increase in antibody levels, versus those
who had a decrease in antibody level. The OR was calcu-
lated as the odds of being a weak responder (i.e. having a
negative change between visits) versus a strong responder
(i.e. having no or positive change) in those who carried the
risk allele versus not (Table 2). Two other genes with sug-
gestive association include integrin aV and MAPK8.
Rs1953090 appears to affect changes in antibody level with
subsequent immunization with homozygous for the minor
allele exhibiting lower antibody levels while homozygotes
for the major allele showing increased responses.
Discussion
Our analysis suggests that polymorphism in TLR genes
may influence antibody responses to CMV gB vaccine.
Specifically, SNPs in TLR7 and IKBKE may influence
these responses. Viral nucleic acids are a major class of
pathogen-associated molecular patterns recognized by
TLRs. TLR3 (dsRNA), TLR7 (ssRNA), TLR8 (ssRNA),
and TLR9 (CpG DNA) signal from the endosome where
degradation of virus particles exposes the viral genome.
Several adapter proteins interact with the TLRs: MyD88
(TLR1, 2, 5, 6, 7, 8, and 9), Mal (or Tirap) (TLR2 and 4)
and TRIF (TLR3). These adapters link TLR proteins to
a downstream signaling pathway including IRAK-1,
IRAK-2, TRAF6, and IKK- abg. The primary conse-
quences of TLR activation include NF-B activation,
Table 1 Associations between SNPs in TLRs and gB-Specific Antibody Responses After 3 doses of CMV vaccine
Gene SNP Location Minor Allele Counts* b Standard Error P value Median ELISA**
TLR7 rs179009 intron C 4/47/91 0.386 0.116 0.001 21102/13194/9769
TLR7 rs179008 coding T 4/34/104 0.304 0.128 0.019 21102/12907/10340
TLR7 rs179018 intron G 4/36/102 0.318 0.130 0.016 16610/12907/10691
TLR7 rs179013 intron T 3/34/105 0.315 0.136 0.022 22940/13501/10530
IKBKE rs1953090 intron C 15/62/64 -0.275 0.097 0.005 10904/9676/14993
TLR3 rs3775292 intron G 5/40/96 0.296 0.117 0.012 10904/13685/9662
IRAK4 rs1838341 intron G 0/16/126 -0.458 0.204 0.027 NA/6394/11378
TLR9 rs5743849 intron T 0/16/126 -0.469 0.211 0.028 NA/6635/11424
*Counts are presented as the number of women homozygous for the minor allele/heterozygous/homozygous for the major allele
**Median ELISA- the median gB antibody titer measured in each of the three groups
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inflammatory cytokine secretion, up-regulation of
immune co-stimulatory molecules and, for a subset of
TLRs, the production of type I interferon.
Herpesviruses activate signaling through TLR2 and
TLR9 [26-28]. TLRs 2, 3, and 9 are involved in innate
immune responses to mouse CMV infection [29,30]. Stu-
dies of human CMV have shown that both gB and gH
activate TLR2 and physically associate with TLR2 and
TLR1 [18]. TLR2 and CD14 recognize CMV virions, and
cells exposed to soluble forms of gB activate NF-kB and
type I interferon [31-33]. CMV gB and gH mediate an
initial signal transduction pathway leading to upregulation
of NF-kB and SP-1, an effect which is inhibited by neutra-
lizing antibodies to gB and gH [19]. A specific single-
nucleotide polymorphism (SNP) in TLR2 was associated
with CMV replication and disease in a cohort of 92 liver
transplant recipients [20].
Surprisingly, we found that specific SNPs in TLR7 were
associated with variability in gB antibodies. SNP
rs179008 is associated with amino acid change in posi-
tion 11 of the TLR7 protein from glutamine to leucine.
Several recent studies provide support for a functional
effect of this SNP [34,35]. TLR7 is generally considered
to function as an intracellular receptor for viral RNAs,
but recent data suggest TLR7 exhibits a much broader
range of specificities and can interact with endogenous
RNAs, as well as bind directly to bacterial pathogens
[36,37]. Among viruses, Epstein Barr virus (EBV), a mem-
ber of the Herpesvirus family, interacts with the TLR7
pathway and enhances B cell proliferation [38]. The role
of TLR7 in the immune response to CMV has been sug-
gested in a study that used plasmacytoid dendritic cells
(PDCs), the main producers of type I IFN in response to
viral infection. Although PDCs were not permissive to
Figure 1 LD Plot of SNPs in TLR7. The blocks are defined by the black triangles using a solid spine of LD in Haploview. The color gradient
refers to the degree of linkage disequilibrium, with red indicating strong LD (D’ is high) and white indicating low LD (D’ is low). Blue coloring
indicates less confidence in the measurement. The actual LD is indicated in the box on a scale of 0-1.
Table 2 Associations between SNPs in TLRs and Changes in Antibody Responses between Second and Third Dose of
CMV Vaccine
GENE SNP ID Location Genotype Counts Fisher’s p- value Median ELISA
IKBKE rs1953090 intron 7/30/31 0.0009319 -14103/-2881/3047
ITGAV rs3795865 intron 1/27/41 0.0123 -36266/-3084/1821
MAPK8 rs17010454 intron 0/8/61 0.02247 0/2862/-1708
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CMV infection, they secreted cytokines after contact with
CMV, including IFN-a secretion that was blocked by
inhibition of TLR7 and TLR9, suggesting an engagement
of the TLR7 and/or TLR9 pathways. Through PDC sti-
mulation, CMV prompted B cell activation, but only
induced antibody production in the presence of T cells
[39].
The best known TLR member expressed in human B
cells is TLR9 [40], but other TLRs including TLR7 are
also expressed. TLR7 ligands activate murine B cells [41]
but TLR7 responsiveness of naive human B cells is con-
trolled by PDC [42]. IFN-a released from PDCs upon sti-
mulation with TLR7 or TLR9 ligands was found to be
responsible for increased TLR7 sensitivity of B cells.
Depletion of PDC from mixed cell cultures (PBMC) lead
to a complete loss of TLR7 ligand-induced B cell prolif-
eration. Our data suggest that TLR7 could interact with
one of the components of the gB vaccine, or that vaccina-
tion induces upregulation of endogenous RNAs subse-
quently recognized by TLR7. Activation of TLR7 upon
gB immunization may induce B-cells to proliferate and
generate antibodies. While the MF59 adjuvant could also
play a role in TLR7 activation, a recent study showed
that MF59 did not activate any of the TLRs in vitro [43].
We note that activation via TLR pathways is not essential
for the function of every adjuvant [44]. Alum adjuvant, as
well as complete and incomplete Freund’s adjuvants,
enhanced antibody responses in mice genetically-engi-
neered to be unable to signal through the major TLR
adapters MyD88.
IKBKE, a noncanonical I-kappa-B kinase (IKK), is
essential for regulating antiviral signaling pathways. It
phosphorylates inhibitors of NF-kappa-B, leading to dis-
sociation of the inhibitor/NF-kappa-B complex and ulti-
mately degradation of the inhibitor. IKBKE is expressed
predominantly in immune cells and tissues, including
peripheral blood leukocytes, spleen, and thymus [45].
IKBKE phosphorylates IRF-3 and is required for its full
activation in CMV-infected smooth muscle cells [46].
Thus, it has a pivotal role in coordinating the activation
of IRF3 and NF-kB in the innate immune response.
Although IRF-3 was initially reported to be activated by
recombinant gB [47], recently Z-DNA binding protein 1,
ZBP1 was suggested as an essential gene for IRF3 activa-
tion by CMV [48]. A recent study demonstrated that
induction of inflammatory cytokines by CMV was
mediated via a TLR-2-dependent activation of NF-B
[31], but it did not specifically evaluate whether IRF-3
was activated in a TLR-2-dependent fashion by CMV. So
far, the literature has only shown TLR-3 and TLR-4 can
induce type I interferon production through IRF-3 activa-
tion. The ability of TLR-7 to induce type I interferon
through IRF-3 has not been studied yet.
Conclusions
This study shows for the first time that host genetics plays
a role in the development of gB antibodies following CMV
immunization. It is unclear whether these polymorphisms
contribute to protective immunity. Future studies will pro-
vide additional understanding of the roles of immune
response genes in CMV immunization and will evaluate
the role of gB in activation of TLR7-related pathways.
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Additional material
Additional file 1: Figure S1. SNPs in ancestry informative markers and
antibody levels in the study population. A principal component analysis
was performed to correct for potential confounding due to ancestry. The
distribution of antibody levels is depicted for African and European
women.
Additional file 2: Figure S2. Quantile-Quantile (QQ) plots of the log
antibody levels QQ plots of log antibody levels and lambda values are
depicted. In the right panel, nothing is done to account for the structure.
On the left panel, the results are adjusted for principal components,
leaving about the same amount of inflation as the case with no
population stratification.
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